Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 2Genitourinary 1Gastrointestinal 1

Conditions

Colorectal Neoplasms 4Stomach Neoplasms 2Melanoma 2Carcinoma, Renal Cell 2Carcinoma, Hepatocellular 2Uveal Melanoma 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Multiple Myeloma 1Lymphoma 1Lung Neoplasms 1Hematologic Neoplasms 1Glioma 1Glioblastoma 1Gallbladder Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colonic Neoplasms 1Carcinoma, Lobular 1Breast Neoplasms 1

Interventions

Bevacizumab 6Nivolumab 5pembrolizumab 4Gemcitabine 4Cisplatin 3regorafenib 2fludarabine 2Sorafenib 2Paclitaxel 2Oxaliplatin 2Leucovorin 2Irinotecan 2Fluorouracil 2Drug Therapy 2Cyclophosphamide 2Azacitidine 2vocimagene amiretrorepvec 1ulixertinib 1temsirolimus 1spartalizumab 1sonidegib 1selinexor 1sargramostim 1sacituzumab govitecan 1ruxolitinib 1rucaparib 1pazopanib 1olutasidenib 1olaparib 1motexafin gadolinium 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioblastoma × Crizotinib × Gastrointestinal × Clear all
NCT01441388 2011-12-20

A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.

Pfizer

Phase 1 Withdrawn
CNSGastrointestinalGenitourinary

Carcinoma, Renal Cell, Glioblastoma, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡